SCHEMBL938097

SCHEMBL938097

Cn1[c]c(Cl)c2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 5/20 0.35
MAPT P10636 4/20 0.35
KDM4E B2RXH2 3/20 0.35
GPR84 Q9NQS5 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NQO2 P16083 2/20 0.34
ALKBH5 Q6P6C2 1/20 0.34
FTO Q9C0B1 1/20 0.34
NPC1 O15118 2/20 0.34
LMNA P02545 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
XBP1 P17861 1/20 0.34
RAB9A P51151 1/20 0.34
PAX8 Q06710 1/20 0.34
TLR9 Q9NR96 1/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
IMPDH2 P12268 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6160593 0.76 GPR3 (0.36) GPR3KDM4ECYP1A2CYP2C19CYP2A6
SCHEMBL2075131 0.76 GPR3 (0.46) GPR3ALDH1A1MAPTKDM4EGPR84
SCHEMBL450895 0.74 GPR3 (0.34) GPR3KDM4ECYP1A2CYP2C19CYP2A6
SCHEMBL7835301 0.71 GPR3 (0.41) GPR3SMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL2202473 0.71 GPR3 (0.41) GPR3SMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL6637894 0.69 ALDH1A1 (0.46) GPR3SMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL2072642 0.67 MAPT (0.45) GPR3SMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL3964359 0.63 CYP1A2 (0.41) GPR3SMN1; SMN2ALDH1A1KDM4ENPSR1
SCHEMBL1809580 0.63 HPGD (0.43) GPR3SMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL21125650 0.63 ALKBH5 (0.63) GPR3ALDH1A1MAPTKDM4EALKBH5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255183-A1 N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS ASTRAZENECA AB (SE) 2008-10-16 US claimed
US-7875606-B2 Herbicides; selectivity between crops and weeds IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2011-01-25 US disclosed
EP-1364946-B1 ISOXAZOLINE DERIVATIVE AND HERBICIDE COMPRISING THE SAME AS ACTIVE INGREDIENT KUMIAI CHEMICAL INDUSTRY CO (JP) 2010-11-24 EP disclosed
US-7833939-B2 Herbicide compositions KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2010-11-16 US disclosed
EP-1405853-B1 ISOXAZOLINE DERIVATIVES AND HERBICIDES KUMIAI CHEMICAL INDUSTRY CO (JP) 2010-11-03 EP disclosed
EP-2186410-A1 Isoxazoline derivative and herbicide comprising the same as active ingredient KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2010-05-19 EP disclosed
EP-2123158-A1 HERBICIDE COMPOSITION Kumiai Chemical Industry CO., LTD. (JP) 2009-11-25 EP disclosed
US-20090062267-A1 L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS ASTRAZENECA AB (SE) 2009-03-05 US disclosed
WO-2008125811-A1 N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS ASTRAZENECA AB (SE) 2008-10-23 WO disclosed
WO-2008093065-A1 L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS ASTRAZENECA AB (SE) 2008-08-07 WO disclosed
US-7238689-B2 Isoxazoline derivative and herbicide comprising the same as active ingredient IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2007-07-03 US disclosed
US-20050256004-A1 Herbicide compositions KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2005-11-17 US disclosed
EP-1405853-A1 ISOXAZOLINE DERIVATIVES AND HERBICIDES KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2004-04-07 EP disclosed
US-6268514-B1 TREATING INDUSTRIAL MATERIALS WITH NITROETHANE COMPOUND FOR PROTECTING AGAINST ATTACK AND DESTRUCTION BY MICROORGANISMS BASF AKTIENGESELLSCHAFT (DE) 2001-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255183-A1 N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS ITGA2B, ITGB1, ITGB5 GPR3 680/4885SMN1; SMN2 1731/4885ALDH1A1 559/4885
US-20050256004-A1 Herbicide compositions DDT, CYP4X1, GLRX3 GPR3 729/4885SMN1; SMN2 3621/4885ALDH1A1 160/4885
US-20090062267-A1 L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS ITGA2B, ITGB1, ITGAL GPR3 1364/4885SMN1; SMN2 1516/4885ALDH1A1 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.